A long-running debate over prescription drug pricing is showing signs of a shift, with new analysis suggesting the market is beginning to reward genuine pharmaceutical innovation more than so-called “me-too” drugs that offer only marginal improvements over existing treatments despite carrying high price tags.
Critics have long argued that the current system props up drugmakers for producing medicines with limited added benefit, while doing too little to incentivise breakthrough treatments for serious or rare conditions. That imbalance has driven up healthcare costs without always delivering meaningful gains for patients.
The latest trends suggest that is starting to change, driven by mounting pressure from insurers, policymakers and patients demanding that drug prices reflect actual value. As a result, pharmaceutical companies are facing stronger incentives to invest in first-in-class treatments rather than incremental variations on existing drugs, a shift that could meaningfully reshape research priorities across the industry.
Source: medicalxpress.com